Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.

The Medical letter on drugs and therapeutics · 2018 · vol. 60(1556) , pp. 158–160 · PMID:30383729 · W4293275511
article OA: closed CC0 ⤵ 2 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist approved for managing endometriosis-associated pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Hormone Antagonists Hydrocarbons, Fluorinated Pain Pyrimidines Administration, Oral Animals Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Hormone Antagonists Hormone Antagonists Humans Hydrocarbons, Fluorinated Hydrocarbons, Fluorinated Pain Pain

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-12T06:13:51.797165+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:31.300640+00:00
License: CC0 · commercial use OK